• Healthcare & Life Sciences

Targeting the USD 425 Billion CRO and CDMO Opportunity


Discover the vital role of Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) in our latest research report. As the industry encounters transformative collaborations, our analysis highlights the trends and service advancements driving pharmaceutical and biotech companies from concept to consumer. 

Our report showcases the strategic partnerships and mergers defining the future of life sciences outsourcing over the past three years. 

Key Highlights of the Report:

  • Driving Market Trends: Explore essential developments fueling progress in the CDMO and CRO sectors 
  • Comprehensive Services Overview: Examine the breadth of services integral to the drug development process 
  • Analysis of EBITDA Multiples: Review the sector’s financial health through EV/EBITDA ratios against the S&P 500, assessing its investment potential 
  • Focused M&A Insights: Detailing M&A drivers, our report spotlights the M&A activity reshaping the life sciences outsourcing landscape 

Why Download This Report? 

Arm yourself with strategic insights into the operational and financial strategies influencing the future of Life Sciences Outsourcing particularly in CDMO and CRO services. Understand the market implications of key business moves, from mergers and acquisitions to Private Equity investments that are directing the sector’s course.

Share article
View More Reports